Policy & Regulations

This channel includes news coverage of healthcare policy and regulations set by Congress, the states, Centers for Disease Control and Prevention (CDC), the Department of Health and Human Services (HHS), U.S. Food and Drug Administration (FDA), and medical associations and societies. 

Thumbnail

Medicare competitive bidding process hurts patients

The Medicare bidding process is hurting patients, according to a new study from the Pacific Research Institute.

Thumbnail

Amid revenue growth, UnitedHealth considers acquiring $2B Tenet subsidiary

UnitedHealth Group is exploring an acquisition of Tenet Healthcare’s healthcare management subsidiary, Conifer Health Solutions, according to the The Wall Street Journal.

CMS opens comment period for Kentucky Medicaid work requirements

After a federal judge blocked work requirements for Medicaid beneficiaries in Kentucky, CMS has opened a pathway for the policy.

Facing pressure from Trump, another drug manufacturer drops price hikes

Novartis, one of the world’s biggest pharmaceutical companies, has paused any price hikes on its drugs for the remainder of 2018.

FDA unveils plan to lower prices, boost competition among drug-makers

The FDA unveiled a new plan to enable market competition for biologics and biosimilars Wednesday, July 18, as part of a larger shift to lower drug prices across the healthcare system.

Thumbnail

Humana hits highest share price ever

With a stake in two post-acute care companies under its belt, health insurer Humana saw its share price hit a new record high last week.

Amazon eyeing investment in Indian pharmacy chain

Retail giant Amazon is in early talk to invest in Medplus, India’s second-largest pharmacy chain, according to FactorDaily.

Thumbnail

HHS diverts $40M to immigration crisis under Trump policy

President Donald Trump’s policy of “zero tolerance” on illegal immigration has led HHS to redirect millions in funding to house migrant children separated from their parents at the border.

Around the web

With generative AI coming into its own, AI regulators must avoid relying too much on principles of risk management—and not enough on those of uncertainty management.

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Trimed Popup
Trimed Popup